1. Executive Summary

2. Introduction
2.1 Psychedelic Drugs: An Overview
2.1.1 History of Psychedelic Drugs
2.1.2 Pros and Cons of Psychedelic Drugs
2.1.3 Major Types of Psychedelic Drugs
2.1.4 Potential Treatment Indications for Psychedelic Molecules
2.1.5 Psychedelic Classification
2.2 Psychedelic Drugs Segmentation: An Overview
2.2.1 Psychedelic Drugs Segmentation by Indication
2.2.2 Psychedelic Drugs Segmentation by Drug Type

3. Global Market Analysis
3.1 Global Psychedelic Drugs Market: An Analysis
3.1.1 Global Psychedelic Drugs Market by Value
3.1.2 Global Psychedelic Drugs Market by Indication (ADHD, MDD, Bipolar, Migraine, Anxiety, Parkinson's Disease, OUD, Alzheimer's Disease, AUD, TUD, Eating Disorder and Narcolepsy)
3.2 Global Psychedelic Drugs Market: Indication Analysis
3.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Psychedelic Drugs Market by Value
3.2.2 Global Major Depressive Disorder (MDD) Psychedelic Drugs Market by Value
3.2.3 Global Bipolar Disorder Psychedelic Drugs Market by Value
3.2.4 Global Migraine Psychedelic Drugs Market by Value
3.2.5 Global Anxiety Psychedelic Drugs Market by Value
3.2.6 Global Parkinson's Disease Psychedelic Drugs Market by Value
3.2.7 Global Opioid Use Disorder (OUD) Psychedelic Drugs Market by Value
3.2.8 Global Alzheimer's Disease Psychedelic Drugs Market by Value
3.2.9 Global Alcohol Use Disorder (AUD) Psychedelic Drugs Market by Value
3.2.10 Global Tobacco Use Disorder (TUD) Psychedelic Drugs Market by Value
3.2.11 Global Eating Disorder Psychedelic Drugs Market by Value
3.2.12 Global Narcolepsy Psychedelic Drugs Market by Value

4. Impact of COVID-19
4.1 Impact of COVID-19
4.1.1 Impact of COVID-19 on Healthcare Sector
4.1.2 Impact of COVID-19 on Psychedelic Drugs Industry

5. Market Dynamics
5.1 Growth Driver
5.1.1 Rising Prevalence of Depression and Mental Disorders
5.1.2 Regulatory Reforms
5.1.3 Developments Relating to Psychedelics
5.1.4 Changing Perceptions
5.1.5 Little Severe Side Effects and Cost effective
5.2 Challenges
5.2.1 Uncertainty around Getting the FDA Approval
5.2.2 Early Stage in Lifecycle of the Psychedelics Industry
5.2.3 Stigma Associated with Psychedelic Drugs Use
5.3 Market Trends
5.3.1 Rising Approval for Additional Psychedelic Drugs
5.3.2 Growing Popularity of Psilocybin
5.3.3 Rising Number of Potential Candidates for Breakthrough Therapy Designation (BTD)
5.3.4 Surging popularity of Micro-dosing in Psychedelics
5.3.5 Emergence of Psychedelic-assisted Psychotherapy (PAP)
5.3.6 Increasing Potential Treatment Indications for Psychedelic Drugs

6. Competitive Landscape
6.1 Global Psychedelic Drugs Market Players by Drug TAM
6.2 Global Psychedelic Drugs Market Players by Psychedelic Related Businesses
6.3 Global Psychedelic Drugs Market Players by Psychedelic-related Clinical Trials
6.4 Global Psychedelic Drugs Market Players by Breakthrough Therapy Designations (BTD) for Psychedelic Substances

7. Company Profiles
7.1 COMPASS Pathways Plc
7.1.1 Business Overview
7.1.2 Business Strategy
7.2 Mind Medicine (MindMed) Inc.
7.2.1 Business Overview
7.2.2 Business Strategy
7.3 Numinus Wellness Inc.
7.3.1 Business Overview
7.3.2 Business Strategy
7.4 Johnson & Johnson
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy

List of Figures
Figure 1: History of Psychedelic Drugs
Figure 2: Pros and Cons of Psychedelic Drugs
Figure 3: Major Types of Psychedelic Drugs
Figure 4: Psychedelic Drugs Segmentation by Indication
Figure 5: Psychedelic Drugs Segmentation by Drug Type
Figure 6: Global Psychedelic Drugs Market by Value; 2018-2020 (US$ Billion)
Figure 7: Global Psychedelic Drugs Market by Value; 2021-2025 (US$ Billion)
Figure 8: Global Psychedelic Drugs Market by Indication; 2020 (Percentage, %)
Figure 9: Global Attention Deficit Hyperactivity Disorder (ADHD) Psychedelic Drugs Market by Value; 2018-2020 (US$ Billion)
Figure 10: Global Attention Deficit Hyperactivity Disorder (ADHD) Psychedelic Drugs Market by Value; 2021-2025 (US$ Billion)
Figure 11: Global Major Depressive Disorder (MDD) Psychedelic Drugs Market by Value; 2018-2020 (US$ Billion)
Figure 12: Global Major Depressive Disorder (MDD) Psychedelic Drugs Market by Value; 2021-2025 (US$ Billion)
Figure 13: Global Bipolar Disorder Psychedelic Drugs Market by Value; 2018-2020 (US$ Billion)
Figure 14: Global Bipolar Disorder Psychedelic Drugs Market by Value; 2021-2025 (US$ Billion)
Figure 15: Global Migraine Psychedelic Drugs Market by Value; 2018-2020 (US$ Billion)
Figure 16: Global Migraine Psychedelic Drugs Market by Value; 2021-2025 (US$ Billion)
Figure 17: Global Anxiety Psychedelic Drugs Market by Value; 2018-2020 (US$ Billion)
Figure 18: Global Anxiety Psychedelic Drugs Market by Value; 2021-2025 (US$ Billion)
Figure 19: Global Parkinson's Disease Psychedelic Drugs Market by Value; 2018-2020 (US$ Billion)
Figure 20: Global Parkinson's Disease Psychedelic Drugs Market by Value; 2021-2025 (US$ Billion)
Figure 21: Global Opioid Use Disorder (OUD) Psychedelic Drugs Market by Value; 2018-2020 (US$ Billion)
Figure 22: Global Opioid Use Disorder (OUD) Psychedelic Drugs Market by Value; 2021-2025 (US$ Billion)
Figure 23: Global Alzheimer's Disease Psychedelic Drugs Market by Value; 2018-2020 (US$ Billion)
Figure 24: Global Alzheimer's Disease Psychedelic Drugs Market by Value; 2021-2025 (US$ Billion)
Figure 25: Global Alcohol Use Disorder (AUD) Psychedelic Drugs Market by Value; 2018-2020 (US$ Million)
Figure 26: Global Alcohol Use Disorder (AUD) Psychedelic Drugs Market by Value; 2021-2025 (US$ Million)
Figure 27: Global Tobacco Use Disorder (TUD) Psychedelic Drugs Market by Value; 2018-2020 (US$ Million)
Figure 28: Global Tobacco Use Disorder (TUD) Psychedelic Drugs Market by Value; 2021-2025 (US$ Million)
Figure 29: Global Eating Disorder Psychedelic Drugs Market by Value; 2018-2020 (US$ Million)
Figure 30: Global Eating Disorder Psychedelic Drugs Market by Value; 2021-2025 (US$ Million)
Figure 31: Global Narcolepsy Psychedelic Drugs Market by Value; 2018-2020 (US$ Million)
Figure 32: Global Narcolepsy Psychedelic Drugs Market by Value; 2021-2025 (US$ Million)
Figure 33: The US Percentage of Adults Showing Symptoms of Anxiety and/or Depressive Disorder; 2019-2020 (Percentage, %)
Figure 34: The US Total Expenditure for Mental Health Services; 2014-2020 (US$ Billion)
Figure 35: The US Number of Clinical Trials on Various Psychedelic Drugs; 2020
Figure 36: Global Psychedelic Drugs Market Players by Drug TAM; 2020 (Patients in Million)
Figure 37: Johnson & Johnson Sales; 2016-2020 (US$ Billion)
Figure 38: Johnson & Johnson Sales by Segments; 2020 (Percentage, %)
Figure 39: Johnson & Johnson Sales by Region; 2020 (Percentage, %)

List of Tables
Table 1: Potential Treatment Indications for Psychedelic Molecules
Table 2: Psychedelic Classification
Table 3: Timeline of Important Regulatory and Legislative Event
Table 4: Key Developments Relating to Psychedelics
Table 5: Global Psychedelic Drugs Market Players by Psychedelic Related Businesses
Table 6: Global Psychedelic Drugs Market Players by Psychedelic-related Clinical Trials
Table 7: Global Psychedelic Drugs Market Players by Breakthrough Therapy Designations (BTD) for Psychedelic Substances